Renal denervation in a patient with a highly tortuous renal artery using a guide extension catheter: a case report

Peijiang Wang*, Jindong Wan, Jixin Hou, Sen Liu and Fei Ran

Abstract

Background: Catheter-based renal denervation (RDN) has been introduced to treat resistant hypertension. Although the technology of RDN has been largely improved, denervation of tortuous renal arteries remains challenging.

Case presentation: This is a case report of a 49-year-old man with drug resistant hypertension. The patient was selected for RDN after ruling out possible causes of secondary hypertension. Computed tomography angiography showed a highly tortuous left renal artery. An Iberis multielectrode ablation catheter failed to reach the target vessel with a regular guiding catheter. A 5-French extension catheter was introduced into the proximal segment of the main left renal artery to provide extra support force, which enabled successful ablation of the highly tortuous left renal artery. His ambulatory blood pressure was significantly decreased at 1 month follow-up.

Conclusions: It is feasible and effective to use a guide extension catheter for denervation of highly tortuous renal arteries. The present study provides a useful method to ablate tortuous and angled renal arteries and branches.

Keywords: Renal denervation, Tortuous renal artery, Resistant hypertension, Extension catheter, Case report

Background

Renal sympathetic overactivity contributes to the development and maintenance of resistant hypertension. Catheter-based radiofrequency renal denervation (RDN) has been introduced to treat resistant hypertension for more than a decade. Previously, single-electrode radiofrequency ablation systems achieved inconsistent blood pressure–lowering effects, throwing RDN into debate. The development of multielectrode radiofrequency ablation systems has improved the reproducibility and completeness of RDN, yielding consistent anti-hypertensive effects [1]. However, denervation of tortuous renal arteries remains challenging. It is extremely difficult to obtain an adequate arterial wall contact at all ablation sites in tortuous renal arteries, which often leads to procedure failure [2]. Patients with tortuous renal arteries are usually excluded from clinical trials of RDN [3], and future studies need to focus on optimal deliverability of ablation to tortuous renal arteries [4]. Therefore, there is lack of clinical evidence or recommendations regarding the strategy for ablating tortuous renal arteries [4, 5]. In this report, we present a RDN strategy for a highly tortuous renal artery using a guide extension catheter.

Case presentation

We present a 49-year-old man with a 5-year history of hypertension. His blood pressure was uncontrolled despite a combination of five different antihypertensive drugs at target doses [6] (valsartan 80 mg, amlodipine 5 mg, bisoprolol 10 mg, hydrochlorothiazide 25 mg, terazosin 5 mg) with optimal patient compliance to therapy. At admission, the average ambulatory blood pressure was 158/100 mmHg with a non-dipper night pattern. The patients had a normal BMI and renal function. He had
left ventricular hypertrophy with a mild left ventricular diastolic dysfunction. The recommended work-up has been done to rule out possible causes of secondary hypertension.

Computed tomography angiography (CTA) showed a highly tortuous left renal artery and a relatively normal right renal artery (Figs. 1a and 2a). Given the diagnosis and evaluation of the resistant hypertension, the patient was eligible and selected for percutaneous RDN. After local anesthesia with lidocaine, a 6-French sheath was placed into the right femoral artery. Renal artery angiography confirmed the high tortuosity of the left renal artery with no stenosis in either left or right renal arteries (Figs. 1b and 2b). Along a guidewire, an Iberis ablation catheter (Multielectrode Renal Denervation System, AngioCare Medical Technology. Shanghai, China [7]) was inserted into the left renal artery. Due to lack of sufficient support force, the ablation catheter failed to reach the target vessel for ablation after several attempts (Fig. 1c). A 5-French GuideZilla
extension catheter (Boston Scientific, Marlborough, MA) introduced into the proximal segment of the main left renal artery to provide extra support force (Fig. 1d). After that, successful ablation was achieved in both upper (Fig. 1e) and lower (Fig. 1f) branches of the left renal artery. Ablation of the right renal artery was successfully performed without using an extension catheter (Fig. 2c). A total of six ablation sites were performed in a spiral fashion in each renal artery. Post-ablation angiography of bilateral renal arteries showed no vasospasm, stenosis, or dissection. No vascular or renal complications occurred during hospitalization.

At 1 month follow-up, the average ambulatory blood pressure was 140/90 mmHg with a significant reduction of 18/10 mmHg, and his renal function was normal. During the 6 months after the procedure, the antihypertensive drugs were decreased from five to three drugs (valsartan 80 mg, amlodipine 5 mg, hydrochlorothiazide 25 mg).

**Discussion and conclusions**

The crucial role of renal sympathetic overactivity in essential hypertension was appreciated decades ago. Overactivation of renal sympathetic nerves raises blood pressure through vasoconstriction and volume/sodium retention mechanisms. Since then, surgical sympathectomy had been attempted to treat patients with hypertension but had been abandoned due to severe side effects [8]. Selective renal sympathetic denervation achieved by catheter-based percutaneous RDN was introduced to treat resistant hypertension in 2009 [9]. This strategy brought new hope of sympathectomy for treating drug-resistant or refractory hypertension. Anatomy of both renal arteries and nerves is always a challenge for this new technology [10]. For example, patients with small, multiple, or highly tortuous renal arteries are usually excluded from clinical trials of RDN [3]. Ablation of small renal arteries has been largely improved by using newly-designed smaller diameter catheters [10], while denervation of highly tortuous renal arteries remains challenging.

Since clinical trials usually exclude patients with highly tortuous renal arteries, there is lack of evidence on how to denervate this type of vessels. According to 2019 Taiwan Consensus Statement on Renal Denervation, a guidewire with strong support is recommended for cases with tortuous and angulated renal arteries [11]. The present study demonstrated successful ablation of a highly tortuous renal artery using a guide extension catheter. A guide extension catheter would provide better support than using a regular guiding catheter. This study provides a novel and feasible strategy for denervation of highly tortuous renal arteries.

In conclusion, it is feasible and effective to use a guide extension catheter for denervation of highly tortuous renal arteries.

**Abbreviations**

RDN: Renal denervation; CTA: Computed tomography angiography.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

PW has drafted and revised the manuscript. PW, JW, JH, SL and FR have performed the renal denervation procedure and collected data. All authors read and approved the final manuscript.

**Funding**

This work was partially supported by a grant from National Natural Science Foundation of China (81970262 to PW). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Availability of data and materials**

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

**Declarations**

**Ethical approval and consent to participate**

This study has been approved by the Institutional Review Board of Chengdu Medical College. Data for this case report has been collected after written informed consent of the patient and in accordance with Good Clinical Practice and the Declaration of Helsinki.

**Consent for publication**

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

**Competing interests**

Not applicable.

**Received**: 11 May 2021   **Accepted**: 5 August 2021  **Published online**: 10 August 2021

**References**

1.  Kjeldsen SE, Fadil Elmula FEM, Persu A. Future of Renal Sympathetic Denervation in the Treatment of Hypertension. J Am Coll Cardiol. 2019;73(13):1643–5.
2.  Aryanon W, Mao H, Adybelli Z, Romano S, Rodighiero M, Reimers B, La Vecchia L, Ronco C. Renal denervation: intractable hypertension and beyond. Cardiorenal Med. 2014;4(1):22–33.
3.  Bhat A, Kuang YM, Gan GC, Burgess D, Denniss AR. An update on renal artery denervation and its clinical impact on hypertensive disease. Biomed Res Int. 2015;2015:607079.
4.  Myat A, Redwood SR, Qureshi AC, Thackray S, Cleland JG, Bhatt DL, Williams B, Gersh BJ. Renal sympathetic denervation therapy for resistant hypertension: a contemporary synopsis and future implications. Circ Cardiovasc Inter. 2013;6(2):184–97.
5.  Lobio MD, Sharp ASP, Kapil V, Davies J, de Belder MA, Cleveland T, Bent C, Chapman N, Dasgupta I, Levy T, et al. Joint UK societies’ 2019 consensus statement on renal denervation. Heart. 2019;105(19):1456–63.
6.  Joint Committee for Guideline R. 2018 Chinese guidelines for prevention and treatment of hypertension-a report of the revision committee of Chinese guidelines for prevention and treatment of hypertension. J Geriatr Cardiol. 2019;16(3):182–241.
7. Jiang XJ, Dong H, Liang T, Zou YB, Xu B, Gao RL. First-in-man report of a novel dedicated radiofrequency catheter for renal denervation via the transulnar approach. EuroIntervention. 2013;9(6):684–6.
8. Page IH, Heuer GJ. A surgical treatment of essential hypertension. J Clin Invest. 1935;14(1):22–6.
9. Krum H, Schlaich M, Whitboum R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–81.
10. Persu A, Maes F, Renkin J, Pathak A. Renal denervation in hypertensive patients: back to anatomy? Hypertension. 2020;76(4):1084–6.
11. Wang TD, Lee YH, Chang SS, Tung YC, Yeh CF, Lin YH, Pan CT, Hsu CY, Huang CY, Wu CK, et al. 2019 Consensus statement of the Taiwan hypertension society and the Taiwan society of cardiology on renal denervation for the management of arterial hypertension. Acta Cardiol Sin. 2019;35(3):199–230.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.